Peptide
Contacts
Fornitori
Peptidi
Esperti
Ricerca
Impara
Comunità
Notizie
Strumenti
Search...
⌘K
Accedi
Iscriviti
Apri menu
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
RESEARCH
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]
RESEARCH
Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]
RESEARCH
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]
RESEARCH
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]
RESEARCH
Hypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]
RESEARCH
Effects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
RESEARCH
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]
RESEARCH
Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]
RESEARCH
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]
RESEARCH
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]
RESEARCH
Hypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]
RESEARCH
Effects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
Solo a fini di ricerca.
Disposizione completa →
Tutti i Contatti
Influencer
Sara Gottfried
𝕏
▶
W